All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact

DONATE

SubtypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2023-08-22T10:33:04.000Z

Pola-R-CHP vs R-CHOEP in young patients with high-risk DLBCL

By Abhilasha Verma, Sabina Ray
Featured
Georg Lenz
Aug 22, 2023
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in DLBCL.

Bookmark this article

During the 17th ICML, the Lymphoma Hub spoke with Georg Lenz, Münster University Hospital, Münster, DE. We asked for a summary of Pola-R-CHP (polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisolone) vs R-CHOEP (cyclophosphamide, doxorubicin, prednisone, rituximab, vincristine and etoposide) treatment in young patients with high-risk diffuse large B-cell lymphoma (DLBCL). Lenz highlights the efficacy and safety data of each treatment for this population of patients.

Pola-R-CHP vs R-CHOEP in young patients with high-risk DLBCL

More about...
Aggressive B-cell lymphomasCyclophosphamideDiffuse large B-cell lymphomaDoxorubicinICML 2023POLARIXPolatuzumab vedotinPrednisoneRituximab

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Related articles

Add bookmark

Key highlights from a descriptive analysis of the POLARIX trial

During the 17th ICML, the Lymphoma Hub spoke to Charles Herbaux, University of Montpellier, Montpellier, FR. We asked, What are the key highlights from the descriptive analysis of the...

Sep 4, 2023
Add bookmark

Key highlights from a descriptive analysis of the POLARIX trial

During the 17th ICML, the Lymphoma Hub spoke to Charles Herbaux, University of Montpellier, Montpellier, FR. We asked, What are the key...

Sep 4, 2023
Add bookmark

POLARIX trial: Is Pola-R-CHP effective and safe in elderly patients with DLBCL?

During the 17th ICML, the Lymphoma Hub spoke to Hervé Tilly, Centre Henri-Becquerel and University of Rouen, Rouen, FR. We asked, Is Pola-R-CHP effective and safe in...

Aug 30, 2023
Add bookmark

POLARIX trial: Is Pola-R-CHP effective and safe in elderly patients with DLBCL?

During the 17th ICML, the Lymphoma Hub spoke to Hervé Tilly, Centre Henri-Becquerel and University of Rouen, Rouen, FR....

Aug 30, 2023

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox